CRISPR Archives

News and Trends 1 Dec 2016

Evotec gets hold of CRISPR in a new Partnership with Merck

Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

CRISPR meets RNAi: a whole new Targeted Therapy

Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […]

November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Nov 2016

How much of a Gamble is Investing in CRISPR?

CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […]

November 15, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 8 Nov 2016

Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals

Evolva is licensing the CRISPR patents of Emmanuelle Charpentier, in a deal with holding company ERS Genomics. This will grant access to the wonder gene-editing technology for one of the most important players in European SynBio. Headquartered in Switzerland, Evolva develops new ways to obtain ingredients and specialty chemicals with brewing and engineered microorganisms. Its […]

November 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 20 Oct 2016

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Oct 2016

The CRISPR Revolution is here, but how can we make it Useful?

By this point, you can’t have escaped hearing about CRISPR. First discovered in the 1980’s, the repeated sequences and their function in bacterial defense systems remained a mystery until almost 10 years ago, when it was hailed as the biggest scientific discovery of the century. Since then, scientists have leveraged the adaptable, heritable mechanism to develop the most powerful gene-editing technology […]

October 10, 2016 - 6 minutesmins - By External Contributor

News and Trends 4 Oct 2016

CRISPR will Win the Nobel Prize, but When? Not this year…

Nobel Prize week has kicked off with the announcement of Physiology and Medicine recipient: it wasn’t the CRISPR crowd, but Yoshinori Ohsumi for his work on autophagy. As Derek Lowe puts it, CRISPR “is absolutely, positively going to win a Nobel; the only question is when.” Well, it didn’t manage last year, nor this year. […]

October 4, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 13 Sep 2016

Reviewing CRISPR, the Scientific Discovery of the Century

What’s happening with CRISPR these days? Another company just filed for an IPO, documents relevant to CRISPR patent war have come to light, research is moving forward, and the therapy is one step closer to the clinic. In this review, we discuss why the exciting new technology and the drama surrounding it: big money, no clinical […]

September 13, 2016 - 8 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2016

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to access its catalogue of genetic anomalies. The collaboration will target diseases arising from gene misregulation. Horizon Discovery has announced a collaboration with Fulcrum Therapeutics, launched earlier this year by Third Rock Ventures, to target diseases caused by gene regulation malfunction. Fulcrum […]

September 7, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Aug 2016

€350M CRISPR Joint Venture now has a Name and an Office

Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest effort to bring the revolutionary gene editing technology to the medical market. This brainchild represents a huge leap of faith, since no preliminary results have been revealed. The Boston launch may accelerate its progress through clinical trials and produce the first […]

August 23, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Jul 2016

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

The problem with CRISPR, is that not many people are actually experts in the field, and there are only a select few who worked on it pre-2013. So how did this UK Startup make a big name for itself in field of the ‘Biotech Breakthrough of the Century’? Desktop Genetics is a startup founded in 2012 by three […]

July 5, 2016 - 4 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CRISPR

Evotec gets hold of CRISPR in a new Partnership with Merck

CRISPR meets RNAi: a whole new Targeted Therapy

How much of a Gamble is Investing in CRISPR?

Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

The CRISPR Revolution is here, but how can we make it Useful?

CRISPR will Win the Nobel Prize, but When? Not this year…

Reviewing CRISPR, the Scientific Discovery of the Century

CRISPR Therapeutics applies to go Public in another Massive IPO

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

€350M CRISPR Joint Venture now has a Name and an Office

“CRISPR is highly fragmented, with too many approaches. We bring it all together”

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!